Expanding Early Detection of Hepatocellular Carcinoma With HelioLiver

Patients diagnosed with early-stage liver cancer have a significantly higher survival rate compared to those diagnosed in later stages, yet screening options and barriers persist. In the latest episode of Exploring AI in Oncology , Waqas Haque, MD, MPH, speaks with Bharat Tewarie, MD, MBA, the CEO of Helio Genomics, about the company’s AI-powered blood test, HelioLiver , and its potential role in detecting hepatocellular carcinoma (HCC), the most common form of liver cancer. Dr. Tewarie shares why liver cancer is a strong use case for blood-based early detection, how HelioLiver may fit into existing workflows, and barriers to overcome for broader adoption.